Logo image
Development of Secondary Acute Myeloid Leukemia in a Pediatric Patient Concurrently Receiving Primary Therapy for Ewing Sarcoma
Journal article   Open access   Peer reviewed

Development of Secondary Acute Myeloid Leukemia in a Pediatric Patient Concurrently Receiving Primary Therapy for Ewing Sarcoma

Brandon R McNew, Benjamin W Darbro, Deqin Ma and David J Gordon
Journal of pediatric hematology/oncology, Vol.39(7), pp.e370-e372
10/2017
DOI: 10.1097/MPH.0000000000000924
PMCID: PMC5772896
PMID: 28816792
url
https://www.ncbi.nlm.nih.gov/pmc/articles/5772896View
Open Access

Abstract

Ewing sarcoma is a pediatric bone and soft tissue sarcoma that requires intensive therapy, which can cause secondary malignancies. We present a rare case of early, treatment-related AML in a pediatric patient concurrently receiving primary therapy for Ewing sarcoma. Despite AML-directed therapy, our patient died secondary to complications of hyperleukocytosis. Cytogenetic and mutation profiling of the leukemia cells revealed the DNA-topoisomerase-II-inhibitor-associated t(9;11)(p22;q23) translocation and clonal KRAS and BRAF mutations. This report highlights the importance of monitoring for treatment-related effects in cancer therapy, as well as the need for novel, less toxic approaches in Ewing sarcoma therapy.
Translocation, Genetic Humans Sarcoma, Ewing - pathology Secondary Prevention Sarcoma, Ewing - drug therapy Leukocytosis Neoplasms, Second Primary Adolescent Fatal Outcome Female Mutation Leukemia, Myeloid, Acute - chemically induced Leukemia, Myeloid, Acute - genetics

Details

Metrics

Logo image